Lynx1 Capital Management LP bought $3.1M of TScan Therapeutics (TCRX)
Executed May 19 2025, disclosed May 21 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 21 2025), the stock returned +17.1% (delay-adjusted); from the execution session (May 19 2025), +27.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Lynx1 Capital Management LP (10% owner) filed 5 Form 4 reports as a reporting entity in the trailing twelve months (5 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Passage Bio, Inc. (PASG). Across 5 priced purchase filings, the average 21-session return was +14.0% from execution and +10.1% from disclosure (delay-adjusted; derived). The largest single filing was $9.8M of CGEM (1,459,641 sh across 3 lots, as filed), executed Oct 8 2025.